海外の治験の状況「1」での検索結果
251件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- A Clinical Trial for Newly Diagnosed High Risk ER+/HER2– (Estrogen Receptor Positive/ Human Epidermal growth factor receptor Negative) Breast Cancer
- High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer MedDRA version: 20.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Brazil, Canada, Colombia, France, Germany, Hungary, Ireland, Israel, Japan, Korea, Republic of, New Zealand, Poland, Portugal, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom, United States
- 2018-10-19
Authorised
- A Phase II study to assess efficacy and safety of a combination chemotheraphy in first-line treatment with Xeloda + Oxaliplatin + Avastin or Xeloda + Irinotecan + Avastin. At progression of disease (second-line treatment) patient will receive Xeloda + Oxaliplatin + Avastin when received Xeloda + Irinotecan + Avastin in first-line or: At progression of disease (second-line treatment) patient will receive Xeloda + Irinotecan + Avastin if recieved Xeloda + Oxaliplatin + Avastin in first-line.
- Histologically or cytologically confirmed carcinoma of the colon and/or rectum with evidence of metastases. Diagnosis of metastatic disease according to RECIST not more than 3 months prior to enrolment No prior chemotherapeutic treatment for metastatic colorectal carcinoma MedDRA version: 18.1 Level: LLT Classification code 10010028 Term: Colorectal cancer Duke's D System Organ Class: 100000004864 MedDRA version: 18.1 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria
- 2011-06-21
Authorised
- Micro-biological and clinical evaluation of the results after adjuvanter laser therapy with 810nm diode laser in frame the parodontologic basis therapy
- Paradontosis
- Austria
- 2010-04-26
Authorised
- Effects of continuous exercise on time spent in euglycemia and inflammation under the treatment of insulin degludec in patients with type 1 diabetes
- Diabetes mellitus Type 1;Therapeutic area: Body processes [G] - Immune system processes [G12]
- Austria
- 2017-04-27
Authorised
- A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
- Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
- Austria, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Spain, Sweden, United Kingdom
- 2007-07-31
Authorised
- International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia
- Philadelphia positive Acute Lumphoblastic Leukemia MedDRA version: 20.0 Level: PT Classification code 10034877 Term: Philadelphia chromosome positive System Organ Class: 10022891 - Investigations MedDRA version: 20.0 Level: LLT Classification code 10000844 Term: Acute lymphoblastic leukaemia System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Canada, Chile, Czech Republic, Denmark, European Union, Finland, France, Germany, Hong Kong, Israel, Italy, Netherlands, Poland, Sweden, Switzerland, United Kingdom, United States
- 2017-10-30
Authorised
- Prospektive multizentrische Phase-III-Studie zur ambulanten Therapie mit Capecitabin versus Cisplatin plus Capecitabin beim fortgeschrittenen Adenokarzinom der Gallenblase und Gallenwege („CISCA-Studie“) - CISCA-Studie
- Karzinome der Gallenblase, Karzinome der extrahepatischen Gallengänge
- Austria
- 2008-02-25
Authorised
- A Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of S-1 as a Single Agent at 30 mg/m2 BID versus 5-FU Bolus Infusion for the Treatment of Patients with Metastatic Pancreatic Cancer Previously Treated with a Gemcitabine Based-Regimen - S-1 Pancreas
- Advanced Pancreatic Cancer MedDRA version: 9.1 Level: LLT Classification code 10033609 Term: Pancreatic carcinoma
- Austria, Denmark, France, Greece, Hungary, Sweden
- 2007-10-25
Authorised
- International, multicenter, randomized (1:1 oral treprostinil (UT-15C): placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are receiving background oral monotherapy
- Pulmonary Arterial Hypertension MedDRA version: 20.0 Level: PT Classification code 10064911 Term: Pulmonary arterial hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Denmark, France, Germany, Greece, India, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Singapore, Sweden, Taiwan, United Kingdom, United States
- 2012-08-01
Authorised
- An open label extension for patients completing study 3119002 to study the effects of oral Levosimendan on breathing function in patients with the disease Amyotrophic Lateral Sclerosis (ALS)
- Amyotrophic Lateral Sclerosis (ALS) br> MedDRA version: 20.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Austria, Belgium, Canada, Finland, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, United Kingdom, United States
- 2019-04-12
